These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17017518)

  • 1. New face of neuromelanin.
    Double KL; Halliday GM
    J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
    Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
    Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.
    Fasano M; Giraudo S; Coha S; Bergamasco B; Lopiano L
    Neurochem Int; 2003 Jun; 42(7):603-6. PubMed ID: 12590943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of α-synuclein in aged human brain associated with neuromelanin accumulation.
    Xuan Q; Xu SL; Lu DH; Yu S; Zhou M; Uéda K; Cui YQ; Zhang BY; Chan P
    J Neural Transm (Vienna); 2011 Nov; 118(11):1575-83. PubMed ID: 21461961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
    Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
    Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin of the human substantia nigra: an update.
    Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
    Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
    Zecca L; Tampellini D; Gerlach M; Riederer P; Fariello RG; Sulzer D
    Mol Pathol; 2001 Dec; 54(6):414-8. PubMed ID: 11724917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.
    Carballo-Carbajal I; Laguna A; Romero-Giménez J; Cuadros T; Bové J; Martinez-Vicente M; Parent A; Gonzalez-Sepulveda M; Peñuelas N; Torra A; Rodríguez-Galván B; Ballabio A; Hasegawa T; Bortolozzi A; Gelpi E; Vila M
    Nat Commun; 2019 Mar; 10(1):973. PubMed ID: 30846695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.
    Good PF; Olanow CW; Perl DP
    Brain Res; 1992 Oct; 593(2):343-6. PubMed ID: 1450944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.